75822-20-7Relevant academic research and scientific papers
Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators
Boehm, Markus,Beaumont, Kevin,Jones, Rhys,Kalgutkar, Amit S.,Zhang, Liying,Atkinson, Karen,Bai, Guoyun,Brown, Janice A.,Eng, Heather,Goetz, Gilles H.,Holder, Brian R.,Khunte, Bhagyashree,Lazzaro, Sarah,Limberakis, Chris,Ryu, Sangwoo,Shapiro, Michael J.,Tylaska, Laurie,Yan, Jiangli,Turner, Rushia,Leung, Siegfried S. F.,Ramaseshan, Mahesh,Price, David A.,Liras, Spiros,Jacobson, Matthew P.,Earp, David J.,Lokey, R. Scott,Mathiowetz, Alan M.,Menhaji-Klotz, Elnaz
, p. 9653 - 9663 (2017)
The chemokine receptor CXCR7 is an attractive target for a variety of diseases. While several small-molecule modulators of CXCR7 have been reported, peptidic macrocycles may provide advantages in terms of potency, selectivity, and reduced off-target activity. We produced a series of peptidic macrocycles that incorporate an N-linked peptoid functionality where the peptoid group enabled us to explore side-chain diversity well beyond that of natural amino acids. At the same time, theoretical calculations and experimental assays were used to track and reduce the polarity while closely monitoring the physicochemical properties. This strategy led to the discovery of macrocyclic peptide-peptoid hybrids with high CXCR7 binding affinities (Ki app > 5 × 10-6 cm/s). Moreover, bioactive peptide 25 (Ki = 9 nM) achieved oral bioavailability of 18% in rats, which was commensurate with the observed plasma clearance values upon intravenous administration.
